Article

Soluble CD40 Ligand in Morbidly Obese Patients: Effect of Body Mass Index on Recovery to Normal Levels After Gastric Bypass Surgery.

JAMA SURGERY (Impact Factor: 4.3). 02/2013; 148(2):151-6. DOI: 10.1001/jamasurgery.2013.419
Source: PubMed

ABSTRACT IMPORTANCE In recent years, the CD40/CD40L system has been implicated in the pathophysiology of severe chronic inflammatory diseases. Recently, obesity has been described as a low chronic inflammatory disease, so this system could also be involved in the inflammatory process. OBJECTIVE To study soluble CD40 ligand (sCD40L) and other factors implicated in coagulation (plasminogen activator inhibitor 1, antithrombin III, and fibrinogen) and inflammation (C-reactive protein) in patients with morbid obesity and different body mass indexes (BMIs) (calculated as weight in kilograms divided by height in meters squared), before and after weight loss induced by bariatric surgery. DESIGN Plasma samples were obtained before and after a bariatric surgery intervention. Several inflammatory markers were then studied (sCD40L, plasminogen activator inhibitor 1, antithrombin III, and C-reactive protein). The values obtained were compared with a control group of nonobese persons. PARTICIPANTS Thirty-four morbidly obese patients undergoing gastric bypass surgery and 22 normal-weight controls matched for age and sex. INTERVENTIONS A Roux-en-Y gastric bypass was performed in morbidly obese patients. MAIN OUTCOME MEASURES Levels of sCD40L, plasminogen activator inhibitor 1, antithrombin III, fibrinogen, and C-reactive protein 12 months after bariatric surgery. RESULTS Obese men showed a tendency for decreased plasma sCD40L levels 1 year after surgery (mean [SEM], 246.5 [70.4] pg/mL before vs 82.2 [23.2] pg/mL after surgery; P < .05), whereas there were not any significant changes in obese women (285.9 [67.5] pg/mL before vs 287.0 [56.9] pg/mL after surgery). Levels of the other markers studied decreased significantly with weight loss in both sexes. However, all other studied markers tend to have higher concentrations in patients with higher BMIs, except for sCD40L, which tended to have lower concentrations in patients with BMIs higher than 55. The decreases with weight loss were lower with higher BMIs for all measurements, except for antithrombin III. CONCLUSIONS AND RELEVANCE Increased BMI, but not sex, influences recovery to normal levels for the markers studied, possibly indicating a worse prognosis.

Download full-text

Full-text

Available from: Juan Antonio Baena, Aug 30, 2015
0 Followers
 · 
211 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: L’adipogenèse, ou la formation d’adipocyte à partir d’une cellule progénitrice, est un processus clé dans le maintien de l’expandabilité du tissu adipeux (TA) sous-cutané, en limitant l’accumulation ectopique de lipides impliquée dans les pathologies associées à l’obésité. Cette revue est axée sur le rôle du microenvironnement du TA dans le contrôle de l’adipogenèse. Les acteurs cellulaires, physiques et moléculaires du microenvironnement sont décrits. Leurs implications dans les disparités d’expansion des TA et leurs contributions aux complications de l’obésité sont abordées.
    Obésité 01/2014; 9(1). DOI:10.1007/s11690-013-0412-7
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:Immune processes contribute to the development of obesity and its complications, such as insulin resistance, type 2 diabetes mellitus and cardiovascular disease. Approaches that target the inflammatory response are promising therapeutic strategies for obesity. In this context, we recently demonstrated that the interaction between the co-stimulatory protein CD40 and its downstream adaptor protein Tumor necrosis factor Receptor Associated Factor (TRAF) 6 promotes adipose tissue inflammation, insulin resistance and hepatic steatosis in mice in the course of diet-induced obesity.Methods:Here, we evaluated the effects of a small-molecule inhibitor (SMI) of the CD40-TRAF6 interaction, SMI 6860766, on the development of obesity and its complications in mice that were subjected to diet-induced obesity (DIO).Results:Treatment with SMI 6860766 did not result in differences in weight gain, but improved glucose tolerance. Moreover, SMI 6860766 treatment reduced the amount of CD45(+) leukocytes in the epididymal adipose tissue by 69%. Especially the number of adipose tissue CD4(+) and CD8(+) T cells and macrophages were significantly decreased.Conclusions:Our results indicate that small-molecule mediated inhibition of the CD40-TRAF6 interaction is a promising therapeutic strategy for the treatment of metabolic complications of obesity by improving glucose tolerance, by reducing the accumulation of immune cells to the adipose tissue as well as by skewing of the immune response towards a more anti-inflammatory profile.International Journal of Obesity accepted article preview online, 13 November 2014. doi:10.1038/ijo.2014.198.
    International journal of obesity (2005) 11/2014; 39(5). DOI:10.1038/ijo.2014.198 · 5.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the past two decades, numerous experimental and clinical studies have established the importance of inflammation and immunity in the development of obesity and its metabolic complications, including insulin resistance and type 2 diabetes mellitus. In this context, T cells orchestrate inflammatory processes in metabolic organs, such as the adipose tissue (AT) and liver, thereby mediating obesity-related metabolic deterioration. Costimulatory molecules, which are present on antigen-presenting cells and naïve T cells in the AT, are known to mediate the crosstalk between the adaptive and innate immune system and to direct T-cell responses in inflammation. In this Perspectives in Diabetes article, we highlight the newest insights in immune cell interactions in obesity and discuss the role of costimulatory dyads in its pathogenesis. Moreover, the potential of therapeutic strategies that target costimulatory molecules in the metabolic syndrome is explored. © 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
    Diabetes 12/2014; 63(12):3982-91. DOI:10.2337/db14-0272 · 8.47 Impact Factor

Similar Publications